The treatment of malignant tumors has changed rapidly and decisively in the last ten years. Since the introduction of Herceptin, we have been talking about personalized oncology therapy, which is now referred to as precision medicine. Hematology/oncology is now undoubtedly the most innovative field in terms of the introduction of potent therapeutics. Harrison's Hematology and Oncology now provides the necessary knowledge for all participants in interdisciplinary tumor conferences based on the latest developments. Checkpoint inhibitors and tyrosine kinase inhibitors are recent examples, followed by PARP inhibitors for ovarian cancer, anti-EGFR antibodies for colorectal cancer, tyrosine kinase inhibitors for lung cancer, BRAF inhibitors for malignant melanoma, and anti-CD20 for malignant lymphoma. The range of new therapeutic approaches is extensive.